Disease Clusters?

Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.

← Back to all clusters

Cluster 18

21 diseases · 45 shared-gene connections
21 Diseases
162 Unique genes
0.197 Avg. similarity score
Adrenocortical carcinoma Most-connected disease (11 links)
Log in to save this analysis

Save This Analysis

Disease Searched: Adrenocortical carcinoma Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵ Connections in cluster ⇵ Significant partners ⇵ Curated genes ⇵
Adrenocortical carcinoma 11 11 1
Choroid plexus carcinoma 11 11 1
Choroid plexus papilloma 10 10 1
B-lymphoblastic leukemia/lymphoma 6 6 19
Urogenital neoplasms 6 6 5
Vulvar lichen sclerosus 6 6 2
Urologic neoplasms 5 5 8
B-cell chronic lymphocytic leukemia 4 4 8
Demyelinating diseases 4 4 11
Li-fraumeni syndrome 4 4 5
Sapho syndrome 4 4 5
B-cell acute lymphoblastic leukemia 3 3 60
Central nervous system neoplasms 3 3 2
Chromosome 17 deletion 3 3 2
Small cell carcinoma 3 3 9
Lymphoblastic leukemia 2 2 57
Familial telangiectasia cancer syndrome 1 1 1
Merkel cell carcinoma 1 1 1
Uinary system neoplasms 1 1 2
granulocytopenia with immunoglobulin abnormality 1 1 1
leukemia, acute myeloid, susceptibility to 1 1 1

Top shared genes (genes linked to 2+ member diseases)

Gene ⇵ Member diseases ⇵ Linked diseases
TP53 14 / 21 Adrenocortical carcinoma, B-cell chronic lymphocytic leukemia, B-lymphoblastic leukemia/lymphoma, Central nervous system neoplasms and 10 more
CDKN2A 5 / 21 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Li-fraumeni syndrome, Urogenital neoplasms and 1 more
FLT3 4 / 21 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, leukemia, acute myeloid, susceptibility to, Lymphoblastic leukemia
IKZF1 3 / 21 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia
PIP4K2A 3 / 21 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia
ARID5B 2 / 21 B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia
ATR 2 / 21 Familial telangiectasia cancer syndrome, Urologic neoplasms
BCR 2 / 21 B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia
CCND1 2 / 21 B-cell chronic lymphocytic leukemia, Urologic neoplasms
CEBPE 2 / 21 B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia
GATA3 2 / 21 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma
GSDMB 2 / 21 B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia
HYOU1 2 / 21 B-cell acute lymphoblastic leukemia, granulocytopenia with immunoglobulin abnormality
IKZF3 2 / 21 B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia
LHPP 2 / 21 B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia
MDM2 2 / 21 Li-fraumeni syndrome, Sapho syndrome
MYC 2 / 21 Demyelinating diseases, Merkel cell carcinoma
PAX5 2 / 21 B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia
SLC2A13 2 / 21 Uinary system neoplasms, Urogenital neoplasms
SULT1A1 2 / 21 B-cell acute lymphoblastic leukemia, Urologic neoplasms
WDR11 2 / 21 Uinary system neoplasms, Urogenital neoplasms
What do these columns mean?
Connections in cluster
How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners
How many of those links are statistically significant (FDR q < 0.05).
Curated genes
Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes)
How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y)
x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count
Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment
Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value
Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster)
Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster)
Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵ Source ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
Transcriptional misregulation in cancer
TP53, BAK1, CEBPA, CEBPE, CSF2, ERG, FLT3, NFKB1, ATM, PBX1, TCF3, ETV6
 KEGG 18 / 198 6.7× 1.62e-10 2.11e-8 ✓ sig.
Cellular senescence
TP53, CDKN2A, NFKB1, TRAF3IP2, ATM, CCND1, HLA-C, MYC, MTOR, RB1, CDKN2B, ATR
 KEGG 16 / 157 7.6× 3.27e-10 3.96e-8 ✓ sig.
Chronic myeloid leukemia
TP53, BAK1, CDKN2A, NFKB1, CCND1, ABL1, BCR, MYC, RB1, BAX, MDM2
 KEGG 11 / 77 10.6× 5.93e-9 5.34e-7 ✓ sig.
Human cytomegalovirus infection
TP53, BAK1, CCL2, CDKN2A, NFKB1, CCND1, PDGFRA, HLA-C, MYC, MTOR, RB1, BAX
 KEGG 16 / 226 5.2× 6.39e-8 4.43e-6 ✓ sig.
Glioma
TP53, BAK1, CDKN2A, CCND1, PDGFRA, MTOR, RB1, IGF1, BAX, MDM2
 KEGG 10 / 76 9.8× 6.70e-8 4.61e-6 ✓ sig.
Stabilization of p53
TP53, CDKN2A, ATM, CHEK2, MDM2
 Reactome 5 / 11 33.7× 1.82e-7 1.10e-5 ✓ sig.
Pathways in cancer
TP53, BAK1, CDKN2A, CEBPA, FLT3, IL7, NFKB1, STAT4, STAT6, CCND1, PDGFRA, ABL1
 KEGG 24 / 533 3.3× 1.89e-7 1.14e-5 ✓ sig.
Human T-cell leukemia virus 1 infection
TP53, CDKN2A, CSF2, NFKB1, ATM, CCND1, TCF3, HLA-C, MYC, RB1, CDKN2B, ATR
 KEGG 15 / 224 5.0× 3.47e-7 1.95e-5 ✓ sig.
Melanoma
TP53, BAK1, CDKN2A, CCND1, PDGFRA, RB1, IGF1, BAX, MDM2
 KEGG 9 / 73 9.1× 5.49e-7 2.90e-5 ✓ sig.
p53 signaling pathway
TP53, CDKN2A, ATM, CCND1, ATR, IGF1, BAX, CHEK2, MDM2
 KEGG 9 / 75 8.9× 6.94e-7 3.54e-5 ✓ sig.
Pancreatic cancer
TP53, BAK1, CDKN2A, NFKB1, CCND1, MTOR, RB1, BAX, VEGFA
 KEGG 9 / 77 8.7× 8.71e-7 4.31e-5 ✓ sig.
Bladder cancer
TP53, CDKN2A, CCND1, MYC, RB1, MDM2, VEGFA
 KEGG 7 / 41 12.7× 1.09e-6 5.25e-5 ✓ sig.
Kaposi sarcoma-associated herpesvirus infection
TP53, BAK1, CSF2, NFKB1, CCND1, HLA-C, MYC, MTOR, RB1, MAP1LC3B2, BAX, GNB1
 KEGG 13 / 196 4.9× 2.42e-6 1.05e-4 ✓ sig.
Acute myeloid leukemia
CEBPA, CEBPE, CSF2, FLT3, NFKB1, CCND1, MYC, MTOR
 KEGG 8 / 68 8.7× 3.43e-6 1.41e-4 ✓ sig.
Small cell lung cancer
TP53, BAK1, NFKB1, CCND1, MYC, RB1, CDKN2B, BAX, FHIT
 KEGG 9 / 93 7.2× 4.32e-6 1.72e-4 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵ GO ID ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
positive regulation of transcription by RNA polymerase II
TP53, CDKN2A, CEBPA, CEBPE, ELK3, ERG, GATA3, IKZF3, IRF1, MYB, NFKB1, STAT4
 GO:0045944 37 / 1,208 3.5× 1.03e-11 3.75e-9 ✓ sig.
regulation of cell cycle
TP53, BAK1, CDKN2A, CEBPA, IRF1, ATM, CCND1, ABL1, BCR, RB1, BAP1, BAX
 GO:0051726 15 / 262 6.6× 9.25e-9 1.56e-6 ✓ sig.
intrinsic apoptotic signaling pathway in response to DNA damage
BAK1, ATM, ABL1, MYC, SIRT1, BAX, CHEK2, TNF
 GO:0008630 8 / 54 17.1× 1.99e-8 3.07e-6 ✓ sig.
positive regulation of gene expression
TP53, CCL2, CDKN2A, CEBPA, CEBPE, CSF2, GATA3, IL7, BCL11A, ATM, P2RX7, KMT2A
 GO:0010628 19 / 504 4.3× 8.14e-8 1.03e-5 ✓ sig.
response to gamma radiation
TP53, BAK1, GATA3, TIGAR, BAX, CHEK2
 GO:0010332 6 / 27 25.6× 9.85e-8 1.20e-5 ✓ sig.
negative regulation of DNA-templated transcription
TP53, ARID5B, CDKN2A, CEBPA, CSF2, ELK3, GATA3, IKZF1, IRF1, MYB, NAB1, NFKB1
 GO:0045892 21 / 631 3.8× 1.33e-7 1.56e-5 ✓ sig.
replicative senescence
TP53, CDKN2A, ATM, ATR, CHEK2
 GO:0090399 5 / 16 36.0× 1.86e-7 2.07e-5 ✓ sig.
regulation of cellular response to stress
HYOU1, RTEL1, ATM, MTOR, ATR
 GO:0080135 5 / 18 32.0× 3.60e-7 3.57e-5 ✓ sig.
embryonic hemopoiesis
SH2B3, GATA3, PBX1, KMT2A, TAL1
 GO:0035162 5 / 18 32.0× 3.60e-7 3.57e-5 ✓ sig.
cell population proliferation
TP53, CEBPA, CSF2, GATA3, CCND1, PBX1, MYC, RB1, BAP1, IGF1, BAX, GNB1
 GO:0008283 13 / 263 5.7× 5.09e-7 4.81e-5 ✓ sig.
post-embryonic development
ARID5B, GATA3, ATM, ABL1, KMT2A, MTOR, BAX, TAL2
 GO:0009791 8 / 82 11.3× 5.55e-7 5.16e-5 ✓ sig.
macrophage differentiation
CEBPA, CEBPE, CSF2, GATA3, SIRT1, VEGFA
 GO:0030225 6 / 37 18.7× 7.20e-7 6.41e-5 ✓ sig.
regulation of cell population proliferation
TP53, CEBPA, CSF2, STAT4, STAT6, PBX1, ABL1, SIRT1, TAL1, TNF, WNT7A
 GO:0042127 11 / 201 6.3× 1.47e-6 1.15e-4 ✓ sig.
cellular response to xenobiotic stimulus
TP53, CEBPA, MYC, RB1, HTR1B, PDE4B, CHEK2
 GO:0071466 7 / 65 12.4× 1.48e-6 1.15e-4 ✓ sig.
spleen development
MYB, TRAF3IP2, PBX1, ABL1, KMT2A, CDKN2B
 GO:0048536 6 / 42 16.5× 1.57e-6 1.20e-4 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵ Disease B ⇵ Similarity score ⇵ Shared genes ⇵ P-value ⇵ FDR q-value ⇵
B-cell acute lymphoblastic leukemia Lymphoblastic leukemia 0.063 7 2.16e-9 1.89e-8 ✓ sig.
B-lymphoblastic leukemia/lymphoma Lymphoblastic leukemia 0.069 5 6.49e-9 5.45e-8 ✓ sig.
B-cell acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma 0.067 5 8.45e-9 6.85e-8 ✓ sig.
Li-fraumeni syndrome Vulvar lichen sclerosus 0.333 2 8.44e-8 5.95e-7 ✓ sig.
Uinary system neoplasms Urogenital neoplasms 0.333 2 8.44e-8 5.95e-7 ✓ sig.
Urogenital neoplasms Vulvar lichen sclerosus 0.333 2 8.44e-8 5.95e-7 ✓ sig.
Li-fraumeni syndrome Urogenital neoplasms 0.222 2 8.43e-7 5.01e-6 ✓ sig.
Li-fraumeni syndrome Sapho syndrome 0.222 2 8.43e-7 5.01e-6 ✓ sig.
B-lymphoblastic leukemia/lymphoma Vulvar lichen sclerosus 0.100 2 1.44e-6 8.26e-6 ✓ sig.
B-cell chronic lymphocytic leukemia Urologic neoplasms 0.133 2 6.60e-6 3.36e-5 ✓ sig.
B-lymphoblastic leukemia/lymphoma Li-fraumeni syndrome 0.087 2 1.44e-5 6.97e-5 ✓ sig.
B-lymphoblastic leukemia/lymphoma Urogenital neoplasms 0.087 2 1.44e-5 6.97e-5 ✓ sig.
Adrenocortical carcinoma Choroid plexus papilloma 0.500 1 6.49e-5 2.32e-4 ✓ sig.
Choroid plexus carcinoma Choroid plexus papilloma 0.500 1 6.49e-5 2.32e-4 ✓ sig.
Adrenocortical carcinoma Choroid plexus carcinoma 0.500 1 6.49e-5 2.32e-4 ✓ sig.
Central nervous system neoplasms Choroid plexus papilloma 0.333 1 1.30e-4 3.91e-4 ✓ sig.
Central nervous system neoplasms Choroid plexus carcinoma 0.333 1 1.30e-4 3.91e-4 ✓ sig.
Choroid plexus carcinoma Chromosome 17 deletion 0.333 1 1.30e-4 3.91e-4 ✓ sig.
Choroid plexus carcinoma Vulvar lichen sclerosus 0.333 1 1.30e-4 3.91e-4 ✓ sig.
Choroid plexus papilloma Chromosome 17 deletion 0.333 1 1.30e-4 3.91e-4 ✓ sig.
Choroid plexus papilloma Vulvar lichen sclerosus 0.333 1 1.30e-4 3.91e-4 ✓ sig.
Adrenocortical carcinoma Central nervous system neoplasms 0.333 1 1.30e-4 3.91e-4 ✓ sig.
Adrenocortical carcinoma Chromosome 17 deletion 0.333 1 1.30e-4 3.91e-4 ✓ sig.
Adrenocortical carcinoma Vulvar lichen sclerosus 0.333 1 1.30e-4 3.91e-4 ✓ sig.
Adrenocortical carcinoma Sapho syndrome 0.167 1 3.25e-4 7.68e-4 ✓ sig.
Choroid plexus carcinoma Sapho syndrome 0.167 1 3.25e-4 7.68e-4 ✓ sig.
Choroid plexus papilloma Sapho syndrome 0.167 1 3.25e-4 7.68e-4 ✓ sig.
Adrenocortical carcinoma Urogenital neoplasms 0.167 1 3.25e-4 7.68e-4 ✓ sig.
Choroid plexus carcinoma Urogenital neoplasms 0.167 1 3.25e-4 7.68e-4 ✓ sig.
Choroid plexus carcinoma Urologic neoplasms 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Choroid plexus papilloma Urologic neoplasms 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Adrenocortical carcinoma Urologic neoplasms 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Familial telangiectasia cancer syndrome Urologic neoplasms 0.111 1 5.20e-4 1.06e-3 ✓ sig.
B-cell chronic lymphocytic leukemia Choroid plexus papilloma 0.111 1 5.20e-4 1.06e-3 ✓ sig.
B-cell chronic lymphocytic leukemia Choroid plexus carcinoma 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Adrenocortical carcinoma B-cell chronic lymphocytic leukemia 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Adrenocortical carcinoma Small cell carcinoma 0.100 1 5.84e-4 1.15e-3 ✓ sig.
Choroid plexus carcinoma Small cell carcinoma 0.100 1 5.84e-4 1.15e-3 ✓ sig.
Choroid plexus papilloma Small cell carcinoma 0.100 1 5.84e-4 1.15e-3 ✓ sig.
Demyelinating diseases Merkel cell carcinoma 0.083 1 7.14e-4 1.33e-3 ✓ sig.
Choroid plexus papilloma Demyelinating diseases 0.083 1 7.14e-4 1.33e-3 ✓ sig.
Choroid plexus carcinoma Demyelinating diseases 0.083 1 7.14e-4 1.33e-3 ✓ sig.
Adrenocortical carcinoma Demyelinating diseases 0.083 1 7.14e-4 1.33e-3 ✓ sig.
B-lymphoblastic leukemia/lymphoma leukemia, acute myeloid, susceptibility to 0.050 1 1.23e-3 1.98e-3 ✓ sig.
B-cell acute lymphoblastic leukemia granulocytopenia with immunoglobulin abnormality 0.016 1 3.90e-3 4.94e-3 ✓ sig.